Key Maintenance Gaps That Prolong Clinical Trial Timelines

Developing a new pharmaceutical drug takes years of research and testing, so when it’s time to move a product to clinical trial, investors are understandably eager to begin as quickly as possible. Once approved, a product is one step closer to becoming publicly available, meaning investors can begin recouping their investment.

New products must go through clinical trials, and while the process varies by country, one thing remains consistent: manufacturing readiness is often the barrier that prevents pharmaceuticals or medical products from advancing into or through clinical trials.

According to the U.S. Food and Drug Administration, product quality issues are the most common deficiencies leading to clinical holds. Often, these problems can be traced back to manufacturers’ maintenance standards. Inconsistent procedures, incomplete or unreliable asset histories, and non-compliant maintenance practices are often responsible for these shortcomings.

Manufacturing standards that pharmaceutical companies must meet

Every pharmaceutical company must comply with Good Manufacturing Practices (GMP) guidelines. These standards govern quality control throughout the entire manufacturing process, and regulatory authorities use these standards to safeguard against the potential risks of product defects and contamination.

FDA 21 CFR Part 11 and its European counterpart, EudraLex – Volume 4, Annex 11, also govern electronic recordkeeping for life sciences companies. These requirements ensure companies are not only meeting the highest maintenance standards, but that maintenance is clearly and thoroughly documented, and records are accurate, accessible, and complete.

The FDA and regulatory bodies in other countries rely on these standards to ensure the identity, strength, purity, and quality of drug products. The standards are clearly laid out, but meeting them presents unique challenges as products approach or continue clinical trials.

Challenges of maintenance compliance as clinical trials progress

As drugs move from the development and testing phases to the clinical trials phase, production must scale to keep up with the increased demand. Even though the products aren’t going to market yet, production has to increase as trials progress through phases (for example, Phase 1 to Phase 3). Additionally, consistently high product quality and thorough documentation are mandatory for audit compliance.

There are five key maintenance gaps that put GMP compliance at risk:

• Inadequate documentation: Most companies have found that paper documentation is inadequate. And while electronic recordkeeping can make documentation easier, it still needs to meet stringent validation requirements to comply with GMP and FDA rules.
• Improperly trained teams: Employees must understand and follow strict procedures for safety protocols, sanitation, and maintenance tasks to ensure compliance.
• Failure to maintain facilities and supplies: Even if employees understand the standards, shortcuts and missed preventive maintenance can jeopardize compliance.
• Poor equipment upkeep or calibration: Regular cleaning and calibration are key to keeping equipment in good working order and ensuring accurate measurements and processes.
• Failure to audit: GMP regulations require manufacturers to conduct regular internal audits; not doing so can lead to compliance failure.

Beyond GMP compliance, maintenance impacts companies’ ability to meet production requirements and keep pace with needs as clinical trials progress through each stage.

What happens when maintenance falls short

Maintenance is a foundational part of the quality system that regulators evaluate during inspections and clinical trial oversight. Shortcomings are operational failures that can significantly impact a company’s ability to advance products through clinical trials, with results including:

1. Equipment downtime: Downtime during critical phases can result in complete product loss. For example, HVAC failures during processes performed in a cleanroom can render the entire product unusable and cause production delays.
2. Poor product quality: In a survey by Pharma Manufacturing, 28% of respondents said that poor product quality was “often” or “very often” caused by machine failures.
3. Rework: Manufacturing errors or poor product quality lead to rework, increasing costs and delaying product availability.
4. Compliance failure: Incomplete or unreliable equipment histories or documentation prevent companies from proving compliance or passing audits.

Each of these failures can lead to or extend clinical trial delays, which then introduce their own set of problems.

The risks that come with clinical trial delays

When maintenance-related issues trigger clinical holds, batch failures, or compliance deficiencies, the resulting delays create serious downstream consequences. These go far beyond added costs. They put patient safety, trial integrity, sponsor timelines, and even the ultimate success of the program at risk.

• Delays in batch release and sample analysis: Clinical trial material must be manufactured, tested, and released under strict GMP conditions before it can be shipped to trial sites. Maintenance gaps can prevent timely batch release or stall critical quality control testing. When batches are held or rejected, sites run out of investigational product, forcing enrollment pauses or treatment interruptions.
• Delays in validation activities: As trials scale from early phase to larger Phase 2/3 studies, companies must validate additional processes, equipment, and cleaning procedures to support increased production volumes. Non-compliant maintenance practices make it impossible to complete validation on schedule. These delays can block the submission of updated chemistry, manufacturing, and controls information required to lift a clinical hold or move to the next trial phase.
• Investigation backlogs that stall trial progress: When maintenance documentation is incomplete or asset histories unreliable, root cause investigations become prolonged and inconclusive. Unresolved investigations can lead to extended clinical holds while regulators demand additional data or corrective actions.
• Pauses in clinical trial progress: Perhaps the most serious risk is when a trial starts successfully but then stalls due to supply shortages or unresolved manufacturing issues. Patients who have already begun receiving the investigational therapy may lose access to a treatment that was stabilizing their disease or improving their quality of life.

These risks compound quickly. A single maintenance-related failure can cascade into weeks or months of delays, millions in additional development costs, eroded investor confidence, and patients left waiting for potentially life-changing therapies. Addressing these risks requires a system that includes compliance, traceability, and reliability throughout the manufacturing process.

How a CMMS keeps clinical trial timelines on track

Maintenance failures are a common, but hidden, risk in manufacturing drugs for clinical trials. A computerized maintenance management system (CMMS) helps keep clinical trials on track by simplifying compliance and streamlining maintenance.

Built-in work order management makes it easy to request work, schedule preventive maintenance tasks, and assign tasks to a technician. The CMMS can require step-by-step maintenance checklists, contain standard operating procedures (SOPs), or hold other documents to make sure every task is completed thoroughly. Technicians can document exactly what they did, and any missed steps are flagged for correction.

The audit trail is an unchangeable record of everything that has happened in the CMMS, and it’s automatically built into the entire process. Automated workflows can route work orders through maintenance, sanitation, supervisory sign-offs, or other required approvals to ensure tasks are completed to the highest standard, and the audit trail keeps track of who did what, when.

Catching failures before they cause any downtime is key, which is why the eMaint CMMS also integrates with predictive maintenance sensors. Teams can get an alert when assets are overheating or showing signs of misalignment, bearing wear, and other failures, so they can fix potential problems before they escalate.

The team at eMaint offers computer systems validation to support electronic records requirements for FDA 21 CFR Part 11 and Eudralex – Volume 4, Annex 11 compliance. Computer systems must be validated upon deployment and again after any changes. Using a validated system ensures your electronic records meet compliance standards.

Taking a product through clinical trials is a high-stakes gamble, but manufacturing errors don’t have to slow you down. See how the eMaint CMMS works with a free demo.